How Does Cannabis Compare to Traditional Treatments for AS? 

Ankylosing spondylitis (AS) is a progressive inflammatory arthritis that primarily affects the spine and sacroiliac joints. Advanced biologics, physiotherapy, and non-steroidal anti-inflammatory drugs (NSAIDs) have been the mainstays of treatment for many years. But as medical cannabis gains popularity, many people are now curious about how it stacks up against conventional AS treatments. 

This article examines that question from a clinically balanced, evidence-based standpoint, revealing the potential and limitations of cannabis in the context of treating AS. 

What Is Ankylosing Spondylitis, and How Is It Usually Treated? 

Inflammation of the spine and sacroiliac joints is a hallmark of AS, a chronic autoimmune disease. If left untreated, it may result in spinal fusion, limited mobility, and permanent impairment.  

Standard treatment approaches include: 

• NSAIDs (e.g., ibuprofen, naproxen): Frequently the first choice for lowering inflammation and easing pain. 

• Biologics: In moderate-to-severe AS, targeted treatments such as IL-17 inhibitors (secukinumab) and TNF inhibitors (adalimumab, etanercept) are now commonplace. 

• Physiotherapy and exercise: Crucial in preserving flexibility, reducing stiffness, and managing fatigue. 

This is the cornerstone of standard AS care and is usually bolstered by routine imaging and rheumatology follow-up. 

Why Is Cannabis Being Considered as an Alternative? 

Cannabis has gained popularity as a treatment for AS for a number of reasons: 

• Pain management: According to some patients, it is helpful in situations where NSAIDs are ineffective or have negative side effects. 

• Sleep improvement: Cannabis, especially indica strains or formulations high in THC, may help reduce sleep disturbances associated with pain at night. 

• Inflammation: According to preclinical research, some cannabinoids may lessen inflammation. 

Cannabis is becoming more and more popular as an alternative arthritis treatment, particularly among people who want to avoid biologic injections or lessen their dependency on medications. 

How Cannabis Works in the Body 

Although there are many active compounds in cannabis, the two most well-known are 

• THC (tetrahydrocannabinol): a psychoactive substance that causes euphoria but also reduces pain and induces sedation. 

• CBD (cannabidiol): Non-intoxicating and extensively researched for its potential anti-inflammatory, anxiolytic, and neuroprotective effects 

The endocannabinoid system, which controls mood, pain perception, and immune response, is influenced by these cannabinoids. Although there is currently little hard data, this is the theoretical foundation for cannabis’ potential influence on inflammatory diseases like AS. 

The main point of the cannabis comparison with standard biologic and non-biologic treatments is made in this section. 

Cannabis vs Traditional Treatments Effectiveness 

When directly comparing cannabis vs treatment options for AS, the evidence tells a complex story: 

• Pain relief: Although results vary, anecdotal evidence and a few observational studies indicate cannabis may help manage pain. On the other hand, the effectiveness of biologics and NSAIDs has been supported by decades of trials. 

• Inflammation control: Improvements in MRI and CRP levels demonstrate how well biologics work to lower systemic inflammation. Cannabis lacks clinical validation but exhibits early promise, especially with CBD. 

• Functionality and progression: It is shown that biologics and physiotherapy maintain mobility and slow down progression. Cannabis does not appear to slow the progression of disease. 

To put it briefly, cannabis can help manage symptoms, but it cannot take the place of AS therapy as it is currently administered. 

Side Effects and Safety Profiles 

There are risks associated with every treatment. When it comes to cannabis, users may encounter: 

• Cognitive side effects (e.g., impaired memory, attention) 

• Mood disturbances (e.g., anxiety, paranoia) 

• Dependency or tolerance buildup 

• Respiratory issues (if smoked) 

Traditional treatments also have known risks: 

• NSAIDs may cause cardiovascular strain or gastrointestinal bleeding.  

• Because biologics suppress the immune system, they may raise the risk of infection. 

• Development of antibodies or injection-site reactions 

Long-term cannabis use is less researched, especially in relation to chronic autoimmune diseases, even though neither strategy is risk-free. This emphasises how carefully it should be incorporated into long-term care plans. 

Legal and Accessibility Issues 

Cannabis remains tightly regulated in the UK: 

• Although it is legal, medical cannabis is rarely prescribed by the NHS for rheumatological conditions. 

• Usually, access is obtained through private clinics, which incur out-of-pocket expenses. 

• On the other hand, NICE guidelines support the routine availability of NSAIDs and biologics on the NHS. 

As a result, standard AS care continues to be the practical default for many patients, leaving cannabis as a theoretical or supplemental option. 

Patient Experiences and Anecdotal Evidence 

There are many patient stories. According to some reports: 

• Reduced use of painkillers or sleep aids 

• Better quality of sleep 

• A feeling of independence and mastery over their symptoms  

However, others note: 

• Variations in the effects of different strains or products  

• Anxiety, lethargy, or dependence 

• Frustration with lack of medical oversight 

Such anecdotes should be treated as personal rather than prescriptive, and decisions should be based on medical advice. Although these anecdotes do contribute to the broader understanding of alternative arthritis treatments, clinical judgement should always take precedence. 

What Does the Research Say? 

Particularly in AS, there is a dearth of cannabis research. Most results are extrapolated from: 

• Chronic pain populations (e.g., back pain, neuropathy) 

• Inflammatory disorders like rheumatoid arthritis or Crohn’s disease 

• Preclinical (animal) studies showing reduced inflammation or pain signals 

On the other hand, large-scale, placebo-controlled trials with established results, safety information, and long-term follow-up support biologics and NSAIDs.  

At present, cannabis comparison to traditional therapies shows promise but lacks the rigour required for guideline inclusion. 

Final Thoughts 

It makes sense that cannabis would be appealing as a tool for managing AS, particularly for people who are coping with chronic pain, adverse drug reactions, or poor treatment outcomes. Anecdotal evidence suggests that it may reduce discomfort or enhance sleep.  

Cannabis, however, lacks the solid evidence base, precise dosage recommendations, and ease of use of conventional methods when compared to well-established AS therapy. Currently, It is best to think of it as a possible supplement to standard care rather than as a replacement for it. 

Patients should discuss their options with a rheumatologist or general practitioner (GP) prior to making any changes to their treatment. Contact LeafEase to book your consultation. 

In the end, managing AS involves integrating lifestyle support, evidence-based medicine, and well-informed individual decision-making. Learn about accessing medical cannabis on LeafEase.